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Introduction: Patients with non-small cell lung cancer with a
sensitizing mutation in the epidermal growth factor receptor (EGFR)
are likely to respond to treatment with an EGFR inhibitor. In some
patients, residual tumor tissue can be visualized for several years
without any signs of progression.
Methods: Two patients with pathologically verified adenocarci-
noma of the lung and multiple bone metastases were monitored after
start of treatment with erlotinib by examining clinical parameters
and imaging of lung tumors and bone metastases. Pretreatment
biopsies and blood samples were examined for the presence of
EGFR mutations, and lobectomy was performed according to stan-
dard procedures after 10 months of treatment in one patient and 30
months in the other.
Results: Both patients responded to treatment with erlotinib and
displayed a mutated EGFR. At the time of surgery, tumor was still
visible in the lungs of both patients, but cancer cells could not be
identified in the resected lung tumor tissue. In one patient, blood
samples were available and the EGFR mutation was detected in the
circulating DNA in the pretreatment blood sample but was no longer
detectable 4 weeks after start of treatment and could not be detected
in any of the following 12 blood samples.
Conclusions: Treatment with erlotinib may induce complete re-
sponse in patients with metastatic non-small cell lung cancer. It
remains to be shown whether treatment with erlotinib can be
discontinued in such patients. The disappearance of EGFR muta-
tions in the DNA of the blood sample early in treatment might be
used as an indicator of response to erlotinib.
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Tyrosine kinase inhibitors (TKIs) targeting the epidermalgrowth factor receptor (EGFR), such as erlotinib (Tar-
ceva) and gefitinib (Iressa), are used for the treatment of
patients with advanced non-small cell lung cancer (NSCLC),
either as second-/third-line therapy after platinum-based dou-
blet chemotherapy or as first-line treatment in the subgroup of
patients harboring specific EGFR mutations in the ATP-
binding domain of the EGFR protein.1–5 Fifty-five to 82% of
patients with a sensitizing EGFR mutation respond to treat-
ment with a TKI compared with 8.9% in an unselected group
of patients with NSCLC,6 making this molecular marker a
strong predictor of response to a TKI. Thus, the gold standard
for the success of TKI therapy is the detection of EGFR
mutations in tumor biopsies. However, in several articles, the
feasibility and utility of EGFR mutation detection in plasma
has been demonstrated.6–8 This method overcomes the prob-
lem with insufficient tumor material in patients with NSCLC,
and serial detection analysis of plasma DNA before and
during treatment with a TKI may prove useful in predicting
early response (if the EGFR mutation disappears) as well as
relapse (if the EGFR mutation reappears).7
Within a few weeks after start of treatment, a dramatic
improvement in quality of life can be observed in many
mutation-positive patients, which may be accompanied by
objective regression.9 But after initial radiographic regres-
sion, residual tumor is often still present. Clinicians tend to
regard these tumor sites as residual disease responsible for
later progression. No data have so far been published dem-
onstrating complete pathological response to erlotinib in
patients with metastatic NSCLC.
Herein, we report two patients who underwent surgical
resection of suspected lung tumors that persisted after pro-
longed treatment with erlotinib. However, on pathological
examination of resected tissue, no tumor cells were identified.
CASE REPORTS
Case 1
A 58-year-old woman diagnosed in 2006 with T2NXM1
adenocarcinoma in the left lung (Figure 1A) and multiple
bone metastases in the vertebral column (Figure 2A) was
referred to the Department of Oncology, Aarhus University
Hospital, for palliative treatment.
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She was a never-smoker but had been exposed to
passive smoke for 30 years at her place of work. A biopsy
from the primary tumor in the left lower lobe revealed
adenocarcinoma at the time of diagnosis. DNA was extracted
from this biopsy, and a deletion in exon 19 (delE746-
T751insI) was identified by massive parallel microreactor
sequencing. She was treated with standard first-line carbo-
platinum/navelbine (four series) but progressed and started
second-line treatment with erlotinib 150 mg/daily simultane-
ously with palliative treatment of the bone metastases in the
spinal column (20 Gy in four fractions from TH5-TH8 and
from L1-L5). The course of the disease was monitored every
6 weeks by 64-row multidetector computed tomography
(MDCT) of the thorax and abdomen, by 1.5T magnetic
resonance imaging (MRI) of the spinal column every 12
weeks, and by fluorodeoxyglucose (FDG)-positron emission
tomography (PET) after 2 and 4 years.
The patient responded to erlotinib with reduction in
pain from bone metastases, reduction in fatigue, and an
improvement in quality of life. The lung tumor regressed
visually. According to the RECIST, the disease was classified
as stable, and a lung tumor could still be identified at each
evaluation (Figures 1A, B). The bone metastases changed
from an osteolytic to an osteosclerotic appearance, also indi-
cating an effect of erlotinib treatment (Figures 2A, B). The
patient had long-lasting skin toxicity (WHO grade 2), leading
to a reduction in erlotinib from 150 to 100 mg/d after 16
weeks. A lobectomy of the left lower lobe was performed
after 30 months of treatment with erlotinib. Before surgery,
the tumor was still visible in the left lower lobe (Figure 1B).
After surgery, the removed lobe was investigated by two
independent pathologists, and no tumor cells, but only a small
atelectatic area, were identified. The patient continued erlo-
tinib 100 mg/d, and follow-up MDCTs of the thorax and
MRIs of spinal column revealed no signs of progression.
After 4 years of treatment with erlotinib, the treatment was
stopped and the patient monitored more intensively, with
MDCT scans every month for 3 months and a FDG-PET after
3 months. There are no signs of progression at present (4
months after cessation of erlotinib treatment), and the pa-
tient’s quality of life has improved significantly after disap-
pearance of the erlotinib side effects.
Case 2
A 43-year-old woman was diagnosed in 2009 with
T2NXM1 adenocarcinoma of the left lung (Figure 3A) with
multiple rib and skull metastases (Figure 4A). She was treated
with standard first-line carboplatinum/navelbine, four series.
Erlotinib was thereafter given as second-line treatment. No
radiotherapy was given. She received the same follow-up as
described for case 1, but FDG-PET was also performed just
before start of erlotinib and showed high uptake in the lung
tumor in the left lower lobe and in multiple lung and bone
metastases.
A biopsy from a large metastasis in the skull (Figure
4A) revealed adenocarcinoma at the time of diagnosis, and a
core needle biopsy from the primary tumor in the left lower
lobe (Figure 3A) taken just before start of treatment with
erlotinib confirmed this diagnosis. A deletion in exon 19
(DelL747-T751) was found in the diagnostic biopsy from the
skull and in the pretreatment blood sample but not in any of
the following 12 blood samples removed every 6 weeks after
start of treatment.
The patient responded to erlotinib, with reduction in
pain from bone metastases, reduction in fatigue, and an
improvement in quality of life. A visible tumor could still be
identified in the lung at each evaluation (Figure 3B). The
bone metastasis in the skull changed appearance from a large
osteolytic and destructive tumor at the time of diagnosis to a
smaller osteosclerotic tumor 4 weeks after start of erlotinib
FIGURE 1. Computed tomography of the chest before (A)
and after 2 years of treatment with erlotinib (B) in a 61-year-
old woman with non-small cell lung cancer and multiple
bone metastases.
FIGURE 2. Magnetic resonance imaging of the vertebra
before (A) and after 2 years of treatment with erlotinib (B) of
a 61-year-old woman with non-small cell lung cancer and
multiple bone metastases.
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treatment, indicating an effect of erlotinib treatment (Figure
4B). The patient had long-lasting skin toxicity (WHO grade
3) leading to a reduction in the dose of erlotinib from 150 to
100 mg/d after 12 weeks of treatment. A segmental resection
of the tumor area (Figure 3B) was performed after 9 months
of treatment with erlotinib. The removed segment of the lung
was investigated by two independent pathologists, and no
tumor cells, but only a small necrotic area, were identified.
The patient continued on erlotinib (100 mg/d) and was
monitored with MDCT and MRI scans every 3 months and a
FDG-PET after 19 months. No progression has been docu-
mented throughout this follow-up.
DISCUSSION
Patients with non-small cell lung cancer harboring a
mutation in the EGF receptor can achieve dramatic response
to treatment with a TKI such as erlotinib, but visible tumor
often still exists. Whether viable tumor cells remain has, at
present, been addressed in only one case report, in which
Takamochi et al.10 performed a surgical resection after 3 to 4
months of treatment with another TKI, gefitinib, in two
patients with locally advanced N2 disease responding to
gefitinib. In these patients, the bulky N2 lymph nodes were
replaced by a fibrous scar, and in one patient, a complete
pathological response was confirmed. In the other patient,
cancer cells with pyknotic nuclei could still be identified.
Both patients had a deletion in exon 19 (E746-A750del).
In our two patients, no cancer cells could be identified
in the resected lung tissue, confirming a complete response in
the lung tumor after treatment with the TKI erlotinib.
In case 2 in which both pre- and posttreatment blood
samples were available, the EGFR mutation could only be
identified in the pretreatment blood sample and disappeared
after start of treatment and was not identified in any of the 12
successive blood samples. Other authors have also found that
the concentration of plasma DNA with EGFR mutations,
measured in serial blood samples, decreased dramatically or
disappeared completely in patients responding to a TKI.7
Therefore, the analysis of serial blood samples may be a
useful predictor of early response to a TKI.
In our case, the disappearance of detectable EGFR
mutations in the plasma may indicate a complete response not
only in the lung tumor but also in the bone metastases,
because the EGFR mutations were also found in the large
skull metastases before start of treatment and could therefore
have served as a reservoir for the EGFR mutations detected in
the blood.
Our results and the results of Takamochi et al. strongly
support the notion that a complete response can be obtained
in patients with metastatic NSCLC. Whether these patients
are in complete remission regarding all metastatic sites has
not been investigated, and the pending question is whether
treatment with erlotinib can be discontinued in these patients.
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